DISCOVERY
Uncover breakthrough
innovations during the drug
discovery phase.
innovations during the drug
discovery phase.
Halloran Consulting Group
Three Key Impacts of ICH E6(R3) on RBQM and Oversight
The International Council for Harmonisation draft guideline, ICH E6(R3), released on May ...
The Good and the Bad– One Year into the EU Clinical Trial Regulation
Earlier this year, we convened at CORE, Halloran’s Clinical Operations Retreat for ...
The Pillars of Driving Change with a Patient-Centric Focus
As a panelist at CORE (Clinical Operations Retreat for Executives) East, hosted in ...
Are You Planning for Success? Essential Role of the Program Manager
Small life science companies often need to ‘do more with less.’ Leaders of these ...
So, You Have Veeva! Four Tips to Maximize Your Value
The use of Veeva systems, a suite of clinical trial solutions, continues to grow. Veeva’s ...
How Strong Project Management Propels Clinical Development Success
The Cost and Challenges of Drug Development
Halloran’s View on FDA’s Draft Guidance on Psychedelic Drugs
The U.S. Food and Drug Administration (FDA) recently issued a draft guidance for industry ...
Halloran Celebrates 25th Anniversary Milestone
[Boston, Massachusetts, July 10, 2023] – Halloran Consulting Group (Halloran) proudly ...
Psychedelics as Therapeutics – What Developers Need to Know
Psychedelics as therapeutics are generating great interest from investors and drug ...
EU MDR Compliance – Why Is Our Industry Still Struggling?
The European (EU) Medical Device Regulation (MDR), adopted in 2017, was a sizeable update ...